kabutan

Astellas Pharma takes third spot in retail investor "buy" rankings on Minkabu

Tue Apr 28, 2026 11:28 am JST Catalyst

Astellas Pharma Inc. <4503> ranked third in buy sentiment among retail investors on the Minkabu platform as of 11:00 a.m. on April 28.

Astellas Pharma shares fell for a sixth straight session in Tokyo on April 28. The drugmaker announced consolidated operating profit of 382.63 billion yen for the fiscal year ended March 2026 after the April 27 market close, a more than nine-fold surge from the previous year. While strong growth in key strategic products and robust guidance for the fiscal year ending March 2027?including a dividend hike to 80 yen from 78 yen?fueled buy sentiment, the stock struggled.

The stock price remained sluggish following the earnings report as investors locked in profits on the news.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles